ABSTRACT
INTRODUCTION
Dendritic cells (DCs) are potent professional antigen-presenting cells and play a key role in initiating primary immune responses. DCs have been considered recently as cellular adjuvants in tumor immunotherapy because of their capacity to enhance antigen presentation. Several advantageous characteristics of DCs have been identified, as compared with other antigen-presenting cells: (a) DCs are capable of uptaking (endocytosis and phagocytosis) and processing an antigenic source in a state of immaturation (1); (b) DCs can present tumorassociated antigen in the context of both MHC class I and class II in association with costimulatory molecules, and thus they can stimulate both cytotoxic T cells and helper T cells (2) ; and (c) DCs can migrate to the draining lymph nodes and spleen, resulting in a systemic immune response (3, 4) . Much attention has been directed to the problem of how and what antigens should be pulsed to DCs in their clinical application as immunotherapy. The most common approach to pulse DCs with tumor antigens is to coculture DCs with tumor-specific peptides or tumor lysate. Recent studies have reported that vaccinations with tumor-associated antigen peptide-loaded DCs elicited antitumor immunity (5) (6) (7) . More recent approaches have used DCs that were transduced with antigen encoding cDNA or RNA (2, 8) . Several viral vectors have been shown to transfer genes encoding antigenic protein or peptide to DCs, and DCs transduced with virus vector encoding tumor-associated antigen were shown to induce specific antitumor immunity in vitro and in vivo (9, 10) .
In this respect, p53 protein is one of the most attractive candidates for antigenic protein, because it is overexpressed in ϳ50% of human malignancies and is expressed at very low levels in normal cells. Mutations in p53 abrogate its function as a tumor suppressor gene and are associated with a prolonged half-life, resulting in marked nuclear and cytoplasmic accumulation of p53 protein. Previous studies have reported successful induction of HLA-A2-or A24-restricted p53-specific CTLs by using p53 peptide-pulsed DCs (11, 12) . Moreover, murine experimental models have demonstrated the ability to target overexpressed p53 protein as a means of achieving tumor rejection (13) . These observations led us to investigate whether p53 could be used potentially for immunotherapy by using the entire p53 sequence as an antigen.
Intratumoral injection has been reported to be an attractive approach for delivering DCs directly to the tumor site. In addi-tion, DCs transduced with a recombinant replication-deficient adenovirus vector are able to effectively present the recombinant protein. In the present study, we demonstrate that murine bone marrow (BM)-derived DCs can be effectively transduced with an adenovirus expressing murine wild-type p53 (wt-p53) gene (Ad-mp53) using the centrifugal method and that intratumoral injection of murine p53-expressing BM-DCs is capable of inhibiting the growth of established syngeneic tumors that express mutated p53. Furthermore, this strategy can enhance systemic immune responses against tumors with high p53 expression.
rabbit complement (Cedarlane, Ontario, Quebec, Canada). The remaining cells were incubated overnight in complete medium, and the nonadherent cells (DC precursor cells) were harvested to be incubated with the complete medium supplemented with recombinant murine-granulocyte macrophage colony-stimulating factor (1000 IU/ml; Genzyme Techne) and recombinant murine-interleukin-4 (1000 IU/ml; Genzyme Techne) for an additional 7 days. On day 3 of culture, 50% of the medium was replaced, and on day 7, nonadherent cells (DCs) were harvested.
Adenovirus-Mediated Gene Transduction into DCs. Gene transfer to DCs was performed using an adenovirus vector with centrifugal force method, as described previously (20) . Briefly, 1 ϫ 10 6 DCs were suspended in 500 l of PBS containing 1% FCS and then mixed with adenoviral vector that was suspended in 500 l of PBS containing 1% FCS. The mixtures of DCs and virus vectors were centrifuged (2000 ϫ g at 37°C) for 2 h. Centrifuged DCs were washed twice in PBS and used for subsequent experiments.
Flow Cytometry. The cell surface expression of DC markers was assessed by flow cytometric analysis. DCs were washed once and stained for 30 min at 4°C with the primary antibody followed by a FITC-conjugated rabbit antimouse IgG. After being washed twice, the cells were analyzed by the FACScan with the window set to exclude dead cells and debris, using CELL Quest software. Ten thousand cells were examined for each determination. Anti-CD11c, -CD80, and -Ia-D b (MHC class II; PharMingen, San Diego, CA) were used as the primary antibodies.
Reverse Transcription-PCR. Molecular analysis of the expression of transduced murine p53 was performed by standard reverse transcription-PCR methods. Total RNA was isolated from untreated DCs or DCs infected with Ad-mp53 or dl312 using RNAzol (Cinna/Biotecx, Friendwood, TX) in a one-step phenol extraction method. Reverse transcription was performed using 0.5 g of total/cytoplasmic RNA reaction to ensure that the amount of amplified DNA was proportional to that of the specific mRNA in the original sample. PCR with specific primers was performed for 20 -30 cycles in a 50-g volume according to the manufacturer's protocol (PCR kit; Perkin-Elmer/ Cetus, Norwalk, CT) using a Perkin-Elmer thermal cycler (Foster City, CA). Specific primers were used for the promoter/ p53 region of Ad-mp53 (sense, 5Ј-CAC GTA CTC TCC TCC CCT CA-3Ј; and antisense, 5Ј-CTC GGG TGG CTC ATA AGG TA-3Ј) and ␤-actin (sense, 5Ј-GCC ATC CTG CGT CTG GAC TTG-3Ј; and antisense, 5Ј-CAC TTG CGG TGC ACG ATG GAG-3Ј), which served as a control. The amplification reactions involved denaturation at 96°C for 1 min, annealing at 59°C for 1 min, and extension at 72°C for 3 min. The PCR products were resolved on 1% agarose gels and visualized by ethidium bromide staining. The density of products was quantified using an image analyzer with ␤-actin as the internal control.
Western Blot Analysis. DCs were collected by trypsinization and washed twice in cold PBS. Cells were then dissolved in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% Triton X-100, and protease inhibitors [0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM 4-(2-aminoethyl) benzenesulfonylfluoride, 10 g/ml leupeptin, 10 g/ml pepstatin, and 1 g/ml aprotinin]. Lysis was performed at 4°C for 30 min, and the lysate was centrifuged at 15,000 rpm. The protein concentration of the supernatant was determined using the BioRad protein determination method (Bio-Rad, Hercules, CA). Equal amounts (15 g) of proteins were electrophoresed under reducing conditions on 12% (w/v) polyacrylamide gels. Proteins were electrophoretically transferred to a Hybond-polyvinylidene difluoride transfer membranes (Amersham, Arlington Heights, IL) and incubated with primary antibodies against murine p53 followed by peroxidase-linked secondary antibody. An Amersham enhanced chemiluminescent Western system (Amersham, Tokyo, Japan) was used to detect secondary probes.
In Vivo Experiments. MethA or MCA-207 tumor cells (1 ϫ 10 6 cells/100 l) were inoculated s.c. into the right and/or left flanks of 6 -12-week-old BALB/c or C57BL/6 mice, respectively. The 3LL tumor cells (1 ϫ 10 6 cells/100 l) were also inoculated s.c. into C57BL/6 mice, and when average tumor diameters reached ϳ5 mm, mice were treated with intratumoral or s.c. injection of HBSS (100 l), untreated DCs (1 ϫ 10 6 cells/100 l), dl312-transduced DCs (1 ϫ 10 6 cells/100 l), or p53-transduced DCs (1 ϫ 10 6 cells/100 l). The s.c. injections were performed Ͼ2.5 cm distant from the tumors. The s.c. MethA, MCA-207, or 3LL tumors were measured with calipers for perpendicular diameters, and tumor volume was calculated using the following formula: tumor volume (mm 3 ) ϭ a ϫ b 2 ϫ 0.5, where a is the longest diameter, b is the shortest diameter, and 0.5 is a constant to calculate the volume of an ellipsoid.
Statistical Analysis. Data are expressed as mean Ϯ SE. Differences in the tumor volumes between the treatment groups were compared using the Student's t test. Statistical significance was defined as P Ͻ 0.05.
RESULTS
Adenovirally Transduced Murine WT-p53 Gene Expression in Murine BM-DCs. BM-DCs generated in vitro with granulocyte macrophage colony-stimulating factor plus interleukin-4 were infected with a replication-deficient adenovirus vector carrying a murine wt-p53 gene under the control of the cytomegalovirus promoter (Ad-mp53) at a multiplicity of infection of 100, 200, or 300. A semiquantitative reverse transcription-PCR assay demonstrated enhanced p53 mRNA expression as early as 24 h after infection (Fig. 1A) . Nishimura et al. (20) reported that adenovirus-mediated gene transduction into DCs was enhanced by centrifugation. Centrifugally transduced DCs showed a marked increase in exogenous p53 expression (Fig. 1B) . In addition, to confirm the functional p53 gene transduction, we conducted Western blot analysis using an antibody against murine p53. Western blotting showed that readily detectable murine p53 protein expression was achieved in BMDCs 36 h after Ad-mp53 infection by the centrifugal method but not in uninfected and dl312-infected DCs (Fig. 1C) . These results suggest that the adenovirus-mediated gene transfer with centrifugal manipulation is highly efficient in murine BM-DCs. There was no apparent toxicity of adenovirus infection up to 300 multiplicity of infection in DCs (data not shown). A, DCs derived from 7-day bone marrow cultures from BALB/c mice with granulocyte macrophage colony-stimulating factor and interleukin-4 were infected with Ad-mp53 at a multiplicity of infection (MOI) of 100, 200, or 300 and subjected to reverse transcription-PCR analysis 24 h after infection. First-strand DNA generated from RNA was amplified using the promoter/p53 primers or ␤-actin primers. The PCR products were visualized on an ethidium bromide gel. B, DCs were exposed to 200 MOI of either dl312 or Ad-mp53 at 37°C for 2 h in combination with or without centrifugation (200 ϫ g) and harvested 24 h after infection. Reverse transcription-PCR was performed with either the primers specific for the promoter/p53 sequence or, as an internal control, the primers that recognized ␤-actin sequences. C, p53 protein expression in murine DCs transduced with Ad-mp53. Western blot analysis of murine p53 protein in Ad-mp53-infected DCs. Bone marrow-derived DCs generated in granulocyte macrophage colony-stimulating factor plus interleukin 4 were infected with either dl312 or Ad-mp53 at a MOI of 200 in combination with centrifugation and analyzed for p53 expression 36 h after infection. Equal loading of samples was confirmed by stripping each blot and reprobing with anti-actin antiserum.
Influence of Ad-mp53 Infection on Differentiation and
Activation of BM-DCs. Recombinant adenovirus infection has been reported to induce maturation and activate human DCs (21, 22) . To determine whether Ad-mp53 infection affected DC activity, we analyzed the cell surface phenotype of DCs infected with either Ad-mp53 or control dl312 by flow cytometric analysis. As shown in Fig. 2 , the intensity of expression of MHC class II, CD11c, and CD80 on Ad-mp53-infected DCs did not differ from that on uninfected or dl312-infected DCs. These results suggest that recombinant adenovirus infection as well as exogenous wt-p53 gene expression had no apparent effect on DC differentiation and activation.
Eradication of Established MethA Tumors by Intratumoral Administration of BM-DCs. To examine the antitumor effect of intratumoral injection of BM-DCs, we established s.c. tumors in BALB/c mice with an injection of 2 ϫ 10 6 MethA sarcoma cells that carry three mutations at codons 132, 168, and 234 in the p53 coding sequence. Mice with palpable s.c. MethA tumors received 3-day courses of intratumoral injections of uninfected, dl312-infected, or Admp53-infected DCs or PBS (mock) on days 7-9, and tumor size was measured. As shown in Fig. 3A , intratumoral administration of DCs transduced with murine wt-p53 gene resulted in substantial MethA tumor growth inhibition; 62.5% of the treated mice showed complete tumor regression. Unexpectedly, 50% of mice that received uninfected or dl312-infected DCs also exhibited apparent tumor regression. All of the control mice died within 80 days after tumor inoculation (7 of 7), whereas 4 of 8 (50%) mice injected with untreated or dl312-infected DCs and 5 of 8 (62.5%) mice treated with Ad-mp53-infected DCs remained tumor-free over an observed period of 120 days (Fig. 3B) .
The experiment was repeated with 5 ϫ (Fig. 4) . In contrast, MethA tumors grew rapidly in naive mice. These results suggest that local DC administration alone might be sufficient to induce substantial inhibition of the growth of MethA tumors as well as rechallenge resistance, probably because of their highly immunogenic properties.
Treatment of Established MCA-207 Tumors by Intratumoral Injection of DCs Transduced with Murine WT-p53
Gene. To assess the ability of Ad-mp53-infected DCs to induce a specific immunological response against p53-expressing tumor cells, we used MCA-207 tumors expressing mutant p53, which are weakly immunogenic, methylcholanthrene-induced fibrosarcomas of C57BL/6 origin. In a representative experiment, MCA-207 tumors that were injected intratumorally with Ad-mp53-infected DCs for 3 consecutive days demonstrated a significant reduction in tumor volume, as compared with animals receiving PBS (mock; P Ͻ 0.05). In contrast, no statistically significant difference in mean tumor volumes was observed between the mock group and the group treated with uninfected or dl312-infected DCs (Fig. 5A) .
The survival curves for all of the four groups were shown in Fig. 5B . All of the control mice without DC treatments died within 62 days of tumor inoculation. Only 1 of 4 mice treated with uninfected DCs or dl312-infected DCs survived for 80 days after tumor inoculation, whereas 2 of 5 mice treated with Admp53-infected DCs survived. These results suggest that local administration of murine p53-transduced DCs exhibits therapeutic efficacy against mutant p53-expressing, weakly immuno- Fig. 2 Effect of dl312 or Ad-mp53 infection on dendritic cell phenotype. Murine dendritic cells generated from bone marrow progenitors were transduced with either dl312 or Ad-mp53 at a multiplicity of infection of 200 in combination with centrifugation and analyzed for surface marker expression by flow cytometry using staining with monoclonal antibodies to the indicated markers 24 h after adenovirus transduction.
Immnotherapy with p53-Expressing Dendritic Cells
Cancer Research. To investigate the mechanisms for the antitumor effect, we histopathologically analyzed MCA-207 tumors injected with Ad-mp53-infected DCs for the distribution of inflammatory and/or immune cells. Histological analysis at 7 days after the first injection of Ad-mp53-infected DCs revealed massive cellular infiltrates at the central portions of the tumors where DCs were injected (Fig. 5C ). In contrast, tumors treated with uninfected DCs showed less intensive cellular infiltrates. Intratumoral injection of PBS as a control induced no cellular infiltrates. These results indicate that the presence of inflammatory infiltrates might be because of transduced p53 expression in DCs rather than DC injection.
Inhibition of MCA-207 Tumor Growth at Distant Sites After Intratumoral Injection of DCs Transduced with Murine WT-p53 Gene.
We also tested whether intratumoral injection of Ad-mp53-transduced DCs could mediate a therapeutic benefit on distant, uninjected MCA-207 tumors in a dual tumor model. MCA-207 tumors were established in both the left and right flanks of C57BL/6 mice, and the growth of tumors in the left flank was assessed after intratumoral inoculation of uninfected, dl312-infected, or Ad-mp53-infected DCs or PBS (mock) into tumors in the right flank. As shown in Fig. 6A , Ad-mp53-infected DCs, but not untreated and dl312-infected DCs, mediated substantial, significant inhibition of the growth of distant MCA-207 tumors compared with tumor growth in the mock-treated group (P Ͻ 0.05). Thus, the antitumor suppression by intratumoral injection of Admp53-transduced DCs was apparently systemic rather than local.
When mutant p53-expressing 3LL tumors and MCA-207 tumors were established in both the left and right flanks of mice, intratumoral administration of Ad-mp53-infected DCs into MCA-207 tumors showed no inhibition of the growth of distant 3LL tumors compared with that in the mock-treated group (Fig.  6B) . These results suggest that intratumoral injection of Admp53-transduced DCs induced systemic antitumor immunity against injected tumors, but not unrelated tumors, even with mutant p53 overexpression.
Therapeutic Advantage of Intratumoral Administration of DCs on MCA-207 Tumors. To additionally define the impact of intratumoral injection of DCs, we compared the antitumor effect of intratumoral injection of Ad-mp53-infected DCs on established MCA-207 tumors with that of s.c. immunization. Mice received three intratumoral injections of Ad-mp53-infected DCs on days 7-9. Another cohort of mice was immunized daily for 3 consecutive days by s.c. administration of DCs transduced with Ad-mp53. Although s.c. immunization with murine p53-transduced DCs resulted in a slower tumor growth rate compared with control groups, this antitumor effect could be significantly enhanced further by intratumoral injections (P Ͻ 0.05; Fig. 7A ). Treatment of MCA-207 tumors with s.c. injection of Ad-mp53-infected DCs was associated with inhibition of tumor growth but not with complete regression; 3 weeks after intratumoral injection of Ad-mp53-infected DCs, however, tumors had completely regressed in 3 of 5 mice (Fig. 7B) . These results suggest that intratumoral immunization with murine p53-expressing DCs have efficient antitumor activity against mutant p53-expressing syngeneic tumors. 
DISCUSSION
Previous studies have suggested that CTL-mediated immunotherapy targeting p53 would be primarily applicable to mutant p53-overexpressing tumors (23); however, the most effective strategy for inducing p53-specific CTLs in vivo remains unclear. DCs are highly efficient antigen-presenting cells and can generate antigen-specific CTLs in a MHC class I-and II-restricted manner. Increased numbers of intratumoral DCs have been reported to be associated with better outcomes in patients with a variety of carcinomas (24 -26) , indicating that intratumoral DCs play an important role in antitumor immune responses. Here, we have shown that intratumoral administration of DCs transduced with murine wt-p53 using an adenovirus vector induced a systemic antitumor effect against mutant p53-expressing murine tumors in vivo and that this effect was greater than that associated with s.c. immunization.
Viral vector-mediated genetic modification of DCs to express tumor antigens or immunomodulatory proteins has been successfully achieved in preclinical animal models of tumor treatment (27, 28) . However, if transgenes have proapoptotic or cell cycle-regulatory functions, it may be difficult to obtain constitutive transgene expression in DCs. Although overexpression of the wt-p53 gene has been known to induce apoptosis in many types of human cancer cells (29, 30) , we were able to generate murine BM-DCs expressing high levels of the wt-p53 gene by adenovirus-mediated transduction combined with centrifugation (Fig. 1) . In addition, recombinant adenovirus infection reportedly induces maturation of DCs via a nuclear factor B-dependent pathway (22) . We found, however, that the adenoviral vector had no detrimental effect on the DC phenotype in our experimental systems (Fig. 2) . Nishimura et al. (20) reported also that infection of adenovirus encoding enhanced green fluorescent protein had little effect on expression of surface markers of DCs, indicating that the effect of recombinant adenovirus infection on DC maturation is controversial.
Intratumoral injection of adenovirus expressing the wt-p53 gene had substantial therapeutic activity in animal models as well as in clinical trials (31, 32) ; the effects, however, seem to be limited within the local areas. Nikitina et al. (33) reported that MethA tumor growth was significantly slowed by immunization of mice with Ad-mp53-transduced DCs (4 ϫ 10 5 and 2 ϫ 10 5 cells were injected i.v. and s.c., respectively). The fact that increased DC numbers within solid tumor masses are associated with improved prognosis (34) suggests the possible application of direct tumoral administration of DCs. We hypothesized that intratumoral administration of Ad-mp53-infected (14) demonstrated that a peptide containing the codon 234 mutation that was identified in MethA p53-induced CD8 ϩ CTLs. Our results, however, were unexpected: DCs delivered intratumorally markedly suppressed the growth of MethA tumors and prolonged the survival of mice, even without Ad-mp53 transduction (Fig. 3) . All of the animals cured of established MethA tumors were protected against subsequent s.c. rechallenge with the same dose of MethA tumor cells (Fig.  4) . One possible explanation for these unexpected results is the strong immunogenicity of MethA tumor cells. DCs could readily acquire antigens by uptake of apoptotic immunogenic tumor cells. Indeed, it has been reported that intratumoral injection of syngeneic DCs resulted in inhibition of murine tumor growth in vivo (17) . Moreover, in the clinical pilot study, DCs mediated biological activity in patients with metastatic tumors after intratumoral injection (35) .
Treatment of mice with intratumoral injections of Admp53-transduced DCs mediated more profound antitumor effects with massive cellular infiltrates than either DCs alone or dl312-transduced DCs when weakly immunogenic MCA-207 tumors were used (Fig. 5) . The possibility that intratumoral injection of Ad-mp53-infected DCs had direct antitumor activity was not excluded. However, we also presented evidence of antitumor effects even in distant established tumors (Fig. 6A) , indicating that p53-expressing DCs administered intratumorally generated a systemic immune response to tumor cells. In addition, we demonstrated that intratumorally delivered DCs infected with Ad-mp53 were more effective than the same cells administered s.c. (Fig. 7 ).
An intriguing question raised by this result is how tumor growth could be efficiently suppressed by intratumoral administration of Ad-mp53-infected DCs. Because recent studies have shown that CTLs specific for several p53 peptides could be generated from peripheral blood mononuclear cells, we speculated that the effector cells responsible for the antitumor activity in our murine models might be p53-specific CTLs. However, we detected a very low p53-specific CTL response against MCA-207 cells after 7-day in vitro stimulation of splenocytes obtained from treated mice (data not shown). The finding that mice treated intratumorally with Ad-mp53-infected DCs demonstrated a therapeutic benefit not only on injected MCA-207 tumors but also on distant, uninjected MCA-207 tumors, but not other unrelated 3LL tumors (Fig. 6) , indicates that the systemic immune response against MCA-207 cells could be induced in vivo. One explanation for the failure of p53-specific lysis in vitro is the lack of acquisition of additional antigens in the process of in vitro stimulation. Although the poor immunogenicity of 3LL tumor cells could not be ruled out, the recognition of other tumor-associated antigens in addition to p53 might be required for the induction of systemic immunity against MCA-207 tumor cells; DCs delivered locally at the site of tumors could phagocytose adjacent tumor cells and present additional tumor antigens in vivo, which might be facilitated by p53 protein overexpression, although additional investigations will be required to confirm this hypothesis.
Because p53 is broadly expressed at low levels in virtually every nucleated cell, whether or not p53 can serve as targets for cancer immunotherapy has remained an open question. In some cases, successful rejection of established tumors by self-tumor antigens could only be achieved in the presence of severe autoimmune responses; in our experimental models, however, none of the mice treated with Ad-mp53-infected DCs showed signs of autoimmune distress (ruffled fur, weight loss, lethargy, or agitation) or histopathological changes in organs at autopsy (data not shown).
In conclusion, we have demonstrated that intratumoral administration of BM-DCs transduced with the wt-p53 gene could elicit a systemic immune response capable of inhibiting the growth of tumor cells harboring mutant p53. Of addi- tional importance, the local delivery of p53-expressing DCs at the site of tumors was apparently more efficient at enhancing the therapeutic efficacy than s.c. administration. It remains to be determined whether or not maturation of DCs after the p53 gene transfer can result in additional therapeutic benefits. Our data, however, provide a preclinical rationale for p53-expressing DC-based therapy, which may be of clinical utility. 
